Table 1.

FDA-approved nanoformulations.

Nanomedicine	Type	Therapeutic Use	Comments
Doxil	Liposome	Cancer (ovarian, multiple myeloma, etc.)	First approved liposomal drug; reduces cardiotoxicity
Abraxane	Nanoparticle-bound albumin	Breast, pancreatic, NSCLC	Enhanced solubility of paclitaxel, higher tumor uptake
Onivyde	Liposome	Pancreatic cancer	Improved drug stability and tumor targeting
Vyxeos	Liposome	Acute myeloid leukemia (AML)	Improved curative effect and survival rate
Marqibo	Liposome	Acute lymphoblastic leukemia	Enhanced targeting and reduced side effects
DepoCyt	Liposome	Neoplastic meningitis	Improved targeting and reduced systemic toxicity